GSA Capital Partners LLP Sells 7,822 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)

GSA Capital Partners LLP cut its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) by 33.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 15,446 shares of the company’s stock after selling 7,822 shares during the period. GSA Capital Partners LLP’s holdings in C4 Therapeutics were worth $88,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Lynx1 Capital Management LP boosted its holdings in shares of C4 Therapeutics by 89.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 6,880,527 shares of the company’s stock valued at $31,788,000 after acquiring an additional 3,245,865 shares during the last quarter. Vanguard Group Inc. lifted its position in C4 Therapeutics by 46.0% during the first quarter. Vanguard Group Inc. now owns 2,920,028 shares of the company’s stock valued at $23,857,000 after purchasing an additional 920,627 shares during the period. Hennion & Walsh Asset Management Inc. boosted its holdings in C4 Therapeutics by 34.7% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 192,364 shares of the company’s stock worth $1,096,000 after purchasing an additional 49,532 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in C4 Therapeutics in the 2nd quarter worth approximately $881,000. Finally, Susquehanna Fundamental Investments LLC raised its stake in C4 Therapeutics by 152.7% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 129,801 shares of the company’s stock valued at $600,000 after buying an additional 78,436 shares during the last quarter. 78.81% of the stock is currently owned by hedge funds and other institutional investors.

C4 Therapeutics Price Performance

Shares of C4 Therapeutics stock opened at $4.38 on Tuesday. C4 Therapeutics, Inc. has a 1-year low of $1.06 and a 1-year high of $11.88. The company’s fifty day simple moving average is $5.64 and its 200-day simple moving average is $5.62. The stock has a market capitalization of $309.18 million, a PE ratio of -2.58 and a beta of 3.04.

C4 Therapeutics (NASDAQ:CCCC) last announced its earnings results on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The company had revenue of $15.36 million for the quarter, compared to analysts’ expectations of $5.95 million. As a group, research analysts anticipate that C4 Therapeutics, Inc. will post -1.48 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. BMO Capital Markets restated an “outperform” rating and issued a $20.00 price target on shares of C4 Therapeutics in a research note on Tuesday, August 6th. Stephens initiated coverage on C4 Therapeutics in a research report on Monday, November 18th. They issued an “equal weight” rating and a $4.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $10.00.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.